

Endophthalmitis rates among patients receiving intravitreal claims analysis

Clinical Ophthalmology

Volume 12, 1625-1635

DOI: [10.2147/opth.s169143](https://doi.org/10.2147/opth.s169143)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Emerging Insights and Interventions for Diabetic Retinopathy. <i>Current Diabetes Reports</i> , 2019, 19, 100.	4.2	28
2	Biotherapeutics and immunogenicity: ophthalmic perspective. <i>Eye</i> , 2019, 33, 1359-1361.	2.1	19
3	Prophylaxis measures for postinjection endophthalmitis. <i>Survey of Ophthalmology</i> , 2020, 65, 408-420.	4.0	21
4	Cost-Utility of Anti-vascular Endothelial Growth Factor Treatment for Macular Edema Secondary to Central Retinal Vein Occlusion. <i>Ophthalmology Retina</i> , 2020, 5, 656-663.	2.4	9
5	Does Pharmaceutical Compounding of Vascular Endothelial Growth Factor Inhibitors for Intravitreal Use Alter the Risk of Post-injection Endophthalmitis?. <i>Ocular Immunology and Inflammation</i> , 2020, , 1-4.	1.8	6
6	MLN4924 inhibits hedgehog signaling pathway and activates autophagy to alleviate mouse laser-induced choroidal neovascularization lesion. <i>Biomedicine and Pharmacotherapy</i> , 2020, 130, 110654.	5.6	6
7	Endophthalmitis Caused by <i>Agrobacterium radiobacter</i> following Intravitreal Aflibercept for Diabetic Retinopathy. <i>Case Reports in Ophthalmology</i> , 2020, 11, 22-27.	0.7	4
8	Brolicizumab and immunogenicity. <i>Eye</i> , 2020, 34, 1726-1728.	2.1	34
9	Clinical Course and Characteristics of Eyes with Recurrent Episodes of Endophthalmitis. <i>Ophthalmology Retina</i> , 2021, 5, 10-15.	2.4	1
10	Effect of Taping Face Masks on Quantitative Particle Counts Near the Eye: Implications for Intravitreal Injections in the COVID-19 Era. <i>American Journal of Ophthalmology</i> , 2021, 225, 166-171.	3.3	20
11	Rates of Suspected Endophthalmitis Following Intravitreal Injections in Clinical Practices in the United States. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2021, 52, 312-318.	0.7	6
12	Future Perspectives of Therapeutic, Diagnostic and Prognostic Aptamers in Eye Pathological Angiogenesis. <i>Cells</i> , 2021, 10, 1455.	4.1	4
13	Intravitreal Injection Therapy: Current Techniques and Supplemental Services. <i>Journal of Vitreoretinal Diseases</i> , 2021, 5, 438-447.	0.7	6
14	Aqueous Chlorhexidine Compared with Povidone-Iodine as Ocular Antisepsis before Intravitreal Injection: A Randomized Clinical Trial. <i>Ophthalmology Retina</i> , 2021, 5, 788-796.	2.4	19
15	Board Certification Is Associated With a Reduced Risk of Endophthalmitis After Intravitreal Injections. <i>Journal of Vitreoretinal Diseases</i> , 2022, 6, 116-121.	0.7	2
16	Prevention of vision-threatening complications in diabetic retinopathy. <i>Current Opinion in Ophthalmology</i> , 2021, Publish Ahead of Print, 590-598.	2.9	5
17	Port delivery system: a novel drug delivery platform to treat retinal diseases. <i>Expert Opinion on Drug Delivery</i> , 2021, 18, 1571-1576.	5.0	18
18	Antiproliferative and Mitochondrial Protective Effects of Apigenin in an Oxygen-Induced Retinopathy <i>In Vivo</i> Mouse Model. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2021, 37, 580-590.	1.4	3

#	ARTICLE	IF	CITATIONS
19	Response to comment on: Dramatic response to intravitreal bevacizumab in hypertensive retinopathy. Indian Journal of Ophthalmology, 2019, 67, 181.	1.1	0
20	CLINICAL OUTCOMES AND TREATMENT COURSE OF EYES WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION FOLLOWING THE DEVELOPMENT OF ENDOPHTHALMITIS. Retina, 2021, 41, 1242-1250.	1.7	5
21	Safety and clinical effectiveness of intravitreal administration of bevacizumab (Lumiere) in patients with neovascular age-related macular degeneration. Experimental and Therapeutic Medicine, 2020, 20, 162.	1.8	0
22	Real-world incidence of endophthalmitis after intravitreal anti-VEGF injection: Common Data Model in ophthalmology. Epidemiology and Health, 2021, , e2021097.	1.9	8
23	Safety and clinical effectiveness of intravitreal administration of bevacizumab (Lumiere [®]) in patients with neovascular age-related macular degeneration. Experimental and Therapeutic Medicine, 2020, 20, 1-1.	1.8	1
24	Future of anti-VEGF: biosimilars and biobetters. International Journal of Retina and Vitreous, 2022, 8, 2.	1.9	26
25	Preventive factors, diagnosis, and management of injection-related endophthalmitis: a literature review. Graefe's Archive for Clinical and Experimental Ophthalmology, 2022, , 1.	1.9	4
26	Intravitreal injections as a leading cause of acute postoperative endophthalmitis—a regional survey in England. Eye, 2021, , .	2.1	0
28	Therapeutic modality aspects in safety and efficacy of ocular drugs. , 2022, , 119-129.		1
29	Long-acting ocular drug delivery technologies with clinical precedent. Expert Opinion on Drug Delivery, 2022, 19, 1285-1301.	5.0	6
30	Incidence and visual outcomes of acute endophthalmitis post intravitreal injection of anti-vascular endothelial growth factors in a single referral center. International Ophthalmology, 0, , .	1.4	1
31	Preclinical Observations of Systemic and Ocular Antidrug Antibody Response to Intravitreally Administered Drugs. AAPS Journal, 2023, 25, .	4.4	1
32	Sustained Biweekly Aflibercept For Refractory Neovascular Age-Related Macular Degeneration: The Prospective TRISTAR Study. Retina, 2022, Publish Ahead of Print, .	1.7	1
33	Seven-year outcome after 1-year fixed regimen of intravitreal aflibercept injections followed by pro re nata treatment for neovascular age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology, 0, , .	1.9	0
34	Vitamin C protects retinal ganglion cells via SPP1 in glaucoma and after optic nerve damage. Life Science Alliance, 2023, 6, e202301976.	2.8	1
35	Potential of TAK-593 Ophthalmic Emulsion for the Treatment of Age-Related Macular Degeneration. Biological and Pharmaceutical Bulletin, 2023, 46, 921-928.	1.4	0
36	The ideal intravitreal injection setting: office, ambulatory surgery room or operating theatre? A narrative review and international survey. Graefe's Archive for Clinical and Experimental Ophthalmology, 2023, 261, 3299-3306.	1.9	2
37	EFFICACY OF VITRECTOMY COMBINED WITH INTRAVITREAL ANTIBIOTICS FOR SEVERE POST-TRAUMATIC ENDOPHTHALMITIS. Retina, 2023, 43, 2003-2009.	1.7	0

#	ARTICLE	IF	CITATIONS
38	Real-world evidence in the use of Bevacizumab in age-related macular degeneration (ArMD): a scoping review. <i>International Ophthalmology</i> , 0, , .	1.4	0
39	Postintra vitreal Injection Endophthalmitis: Incidence, Characteristics, Management, and Outcome. <i>Journal of Ophthalmology</i> , 2023, 2023, 1-9.	1.3	1
40	Eye Infections. <i>New England Journal of Medicine</i> , 2023, 389, 2363-2375.	27.0	1